RTP Mobile Logo
Defining Value and Quality in Cancer Care: Implications for the Practicing General Oncologist
Released December 2015

Roundtable participants include Drs Patricia A Ganz, Lowell L Hart, Bruce E Hillner, Michael Kolodziej, Lowell E Schnipper and John D Sprandio. (Audio Content)

CE Disclosures and Faculty Information

    Healthcare delivery and its related costs represent the largest and fastest-growing sector of the United States economy. However, this significant investment has not translated into longer life expectancies for US citizens. Most policy makers and governing bodies agree that this situation is unsustainable and, more importantly, irresponsible, given the lack of correlation between expenditures and outcomes for the public at large. Perhaps equally important, recent shifts in how institutions and healthcare professionals are or will be compensated have generated uncertainty and questions among practicing clinicians. As such, there is a clear requisite for additional resources designed to assist medical oncologists and other allied cancer professionals in not only better understanding why significant changes are needed but also describing how specific initiatives, programs and models will potentially achieve these important goals. This CME program uses a roundtable discussion with a diverse group of leaders in this field to empower clinicians to continue dialoguing about the relevance of quality and value, provide them with important information and give them confidence that their participation can make a difference in the care delivered at the institutional and patient levels.


    • Develop a better understanding of evolving quality-centered healthcare delivery systems, with a particular emphasis on defining, assessing and achieving performance measures specific to the care of patients with cancer.
    • Review examples of alternative and/or investigational cancer delivery models (eg, oncology medical homes, cancer pathways, et cetera) that attempt to improve the quality, efficiency and affordability of care for patients with cancer.
    • Identify opportunities for medical oncologists to improve the coordination of care for patients with cancer within their institution or local healthcare system.
    • Define opportunities for the medical oncologist and his/her support staff to foster shared decision-making and heighten the engagement and satisfaction of patients and family members in their cancer care journey.
    • Outline learning platforms being instituted by governing bodies to provide practicing oncologists with continuous feedback regarding the comparable effectiveness and quality of care being delivered in their own practices.
    • Summarize the effects of rising healthcare costs or volume-based models on oncology practices.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue


    CME credit is no longer available for this issue

    This CME activity contains an audio component.

    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — Drs Ganz and Kolodziej have no relevant conflicts of interest to disclose. The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr HartContracted Research: Genentech BioOncology, Lilly, Novartis Pharmaceuticals Corporation; Speakers Bureau: Genentech BioOncology, Novartis Pharmaceuticals Corporation. Dr HillnerConsulting Agreement: Bristol-Myers Squibb Company. Dr SchnipperAdvisory Committee: eviti Inc; Consulting Agreement: Merck; Editor-in-Chief: UpToDate. Dr SprandioContracted Research and Speakers Bureau: Genentech BioOncology.

    MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, ImmunoGen Inc, Incyte Corporation, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Astellas Pharma Global Development Inc/Medivation Inc, Celgene Corporation, Genentech BioOncology, Lilly and Teva Oncology.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Release date: December 2015
    Expiration date: December 2016

Acknowledge and close

Listen to audio:
Defining Value and Quality in Cancer Care: Implications for the Practicing General Oncologist
Released December 2015

Roundtable participants include Drs Patricia A Ganz, Lowell L Hart, Bruce E Hillner, Michael Kolodziej, Lowell E Schnipper and John D Sprandio. (Audio Content)

Read print: